780TiP - Safety and Efficacy of Albumin-Bound Paclitaxel and Oxaliplatin and S-1 as First-Line Treatment of Patients with advanced Gastric Cancer

Abstract

ABSTRACT Background Nanoparticle albumin-bound paclitaxel (nab-paclitaxel) is a novel formulation of paclitaxel that does not require solvents such as polyoxyethylated castor oil and ethanol. Use of these solvents has been associated with toxic response, including hypersensitivity reactions and prolonged sensory neuropathy. This study was conducted to evaluate the efficacy and safety of combination chemotherapy with nab-paclitaxel plus oxaliplatin and S-1 as first-line treatment for patients with advanced gastric cancer. Patients and methods Eligible patients (pts) with histologically confirmed advanced gastric cancer, Results From February 2011 to May 2012, total of 16 pts were enrolled, 13 pts received the study treatment, and 13 pts were eligible. Median age was 60, male/female was 3/10, PS:0/1/2 was 3/6/4 . A median of 5 cycles was administered (range, 3-6). ORR was 61.5% (8 of 13) and DCR (disease control rate: rate of CR + PR + SD) was 92.3% (12 of 13) for all eligible patients. The median follow-up time was 10.5 months, the median PFS was 6.3 months. In addition, other secondary endpoints of efficacy are under investigation. Hematological toxicity was mild; grade 3/4 neutropenia was noted in only 7.7% of patients. Alopecia was the most common non-hematological toxicity; Grade 3 alopecia occurred in 5 patients (38.5%). Conclusions Combination chemotherapy of albumin-bound paclitaxel with oxaliplatin and S-1 as first-line chemotherapy is effective and well tolerated in patients with advanced gastric cancer. Disclosure All authors have declared no conflicts of interest.